| 1 | then | 18,090 |
| 2 | adoptively | 13 |
| 3 | results- | 7 |
| 4 | thence | 7 |
| 5 | chd2 | 6 |
| 6 | strupp | 6 |
| 7 | hilleke | 5 |
| 8 | dobmax | 4 |
| 9 | gan-stagnancy | 4 |
| 10 | hspb2b3 | 4 |
| 11 | lanphear | 4 |
| 12 | s7c15 | 4 |
| 13 | β-erythroidine | 4 |
| 14 | 5-insp7 | 3 |
| 15 | brittain | 3 |
| 16 | fodders | 3 |
| 17 | kindly | 3 |
| 18 | pre-mir-125b | 3 |
| 19 | shedded | 3 |
| 20 | supracrestally | 3 |
| 21 | three.we | 3 |
| 22 | trans-mdmar | 3 |
| 23 | 2011were | 2 |
| 24 | 42,742 | 2 |
| 25 | 5,344 | 2 |
| 26 | 5,6,11-trideoxyttx | 2 |
| 27 | akhawaynī | 2 |
| 28 | arachnia | 2 |
| 29 | bignami | 2 |
| 30 | biobody-78 | 2 |
| 31 | butylidenephthalide | 2 |
| 32 | cr-calu1 | 2 |
| 33 | cys-gly | 2 |
| 34 | dogwood | 2 |
| 35 | early-responders | 2 |
| 36 | ecfp-hspb6 | 2 |
| 37 | edsuvmean | 2 |
| 38 | evocarpine | 2 |
| 39 | il-12/il-10 | 2 |
| 40 | irm2 | 2 |
| 41 | l-gly | 2 |
| 42 | mandarin-speakers | 2 |
| 43 | no-cells | 2 |
| 44 | pathomorphologically | 2 |
| 45 | polythiazide | 2 |
| 46 | postflap | 2 |
| 47 | psca-hsp | 2 |
| 48 | tbody-tscrotum | 2 |
| 49 | tranquileyes™ | 2 |
| 50 | tribally | 2 |
| 51 | tymofyeyev | 2 |
| 52 | δgel1δgel7δcwh41 | 2 |
| 53 | 'assess | 1 |
| 54 | +3187a-g. | 1 |
| 55 | 0.47±0.26 | 1 |
| 56 | 02/2010 | 1 |
| 57 | 06.07.1999 | 1 |
| 58 | 1-cyano-4,5-epithiopentane | 1 |
| 59 | 1.4±1.4 | 1 |
| 60 | 1.94±2.31 | 1 |
| 61 | 10-μl | 1 |
| 62 | 11-hete | 1 |
| 63 | 11.7±2.7 | 1 |
| 64 | 13,049 | 1 |
| 65 | 13,658 | 1 |
| 66 | 16,454 | 1 |
| 67 | 16mls | 1 |
| 68 | 2.57/1,000 | 1 |
| 69 | 2.60-folds | 1 |
| 70 | 20,020 | 1 |
| 71 | 20,654 | 1 |
| 72 | 20/40°c | 1 |
| 73 | 20/twice | 1 |
| 74 | 3.3-times | 1 |
| 75 | 3894 | 1 |
| 76 | 4-methoxyquinolone-decayed | 1 |
| 77 | 405/487 | 1 |
| 78 | 41,831 | 1 |
| 79 | 5,494 | 1 |
| 80 | 5,762 | 1 |
| 81 | 5,997 | 1 |
| 82 | 5α/5β-thf | 1 |
| 83 | 6-acid | 1 |
| 84 | 6g/l | 1 |
| 85 | 82/92 | 1 |
| 86 | 83,973 | 1 |
| 87 | 8361 | 1 |
| 88 | 84,646 | 1 |
| 89 | 8638 | 1 |
| 90 | 9,318 | 1 |
| 91 | acedapsone | 1 |
| 92 | actts | 1 |
| 93 | agurya | 1 |
| 94 | alpha-2b/ribavirin | 1 |
| 95 | alpha7beta1 | 1 |
| 96 | anamnestically | 1 |
| 97 | androstane-3α,17β-diol-17-glucuronide | 1 |
| 98 | anitschkow | 1 |
| 99 | anti-c-src | 1 |
| 100 | apolipoprotein-b/ciii | 1 |
| 101 | apxs | 1 |
| 102 | avf/taf | 1 |
| 103 | avicenol-c. | 1 |
| 104 | b-surgery | 1 |
| 105 | benchmrk-2 | 1 |
| 106 | bmp-iir | 1 |
| 107 | boc-deprotection | 1 |
| 108 | buzzes | 1 |
| 109 | c-ha-ras | 1 |
| 110 | c-maltodextrin-glucose | 1 |
| 111 | c-mets | 1 |
| 112 | cd11a-mrna | 1 |
| 113 | cephtriaxon | 1 |
| 114 | cfr=stress | 1 |
| 115 | cholesterol-4-14c | 1 |
| 116 | cl-alb | 1 |
| 117 | co-renitec | 1 |
| 118 | conducted.when | 1 |
| 119 | conjugatively | 1 |
| 120 | conrardy | 1 |
| 121 | coprologically | 1 |
| 122 | csf-oligosaccharides | 1 |
| 123 | cystolithopaxy | 1 |
| 124 | d-mannono-1,4-lactone | 1 |
| 125 | d2-4 | 1 |
| 126 | das-remission | 1 |
| 127 | demets.2 | 1 |
| 128 | desensitization-was | 1 |
| 129 | dft-pbe | 1 |
| 130 | diacetylation | 1 |
| 131 | echinocytosis | 1 |
| 132 | electroclinically | 1 |
| 133 | engenderhealth | 1 |
| 134 | epicutaneously | 1 |
| 135 | ezetimibe+phytosterols | 1 |
| 136 | fads2-activities | 1 |
| 137 | fes-therapy | 1 |
| 138 | financially-equipped | 1 |
| 139 | fluticasone.ciclesonide | 1 |
| 140 | folk-healers | 1 |
| 141 | gate-control-theory | 1 |
| 142 | giao-hf/6-31g*//b3lyp/6-31g* | 1 |
| 143 | gln13 | 1 |
| 144 | h-alpha | 1 |
| 145 | h460-were | 1 |
| 146 | habert | 1 |
| 147 | headache.we | 1 |
| 148 | hf.we | 1 |
| 149 | his176 | 1 |
| 150 | human-colon-15/mdr | 1 |
| 151 | hydroxychlorochine | 1 |
| 152 | hyposalinity | 1 |
| 153 | i1+3 | 1 |
| 154 | ibis2 | 1 |
| 155 | id9 | 1 |
| 156 | iliacs | 1 |
| 157 | included.oral | 1 |
| 158 | inf-10 | 1 |
| 159 | jdp2 | 1 |
| 160 | kammerman | 1 |
| 161 | kruckman | 1 |
| 162 | lambo | 1 |
| 163 | lc/pda/ms | 1 |
| 164 | lennon | 1 |
| 165 | lidocaine-desipramine | 1 |
| 166 | long-running | 1 |
| 167 | lower.. | 1 |
| 168 | lvring→rv-were | 1 |
| 169 | m-2were | 1 |
| 170 | masssensation | 1 |
| 171 | me/ge | 1 |
| 172 | meaningful-has | 1 |
| 173 | mip1-β | 1 |
| 174 | mlvss | 1 |
| 175 | mn4 | 1 |
| 176 | mock-vector | 1 |
| 177 | mtor2 | 1 |
| 178 | muses | 1 |
| 179 | n-deacylation | 1 |
| 180 | naringenin-receptor | 1 |
| 181 | nmeps | 1 |
| 182 | non-platform | 1 |
| 183 | nonradiologists | 1 |
| 184 | oil-yielding | 1 |
| 185 | ornish-were | 1 |
| 186 | oxaceprolin | 1 |
| 187 | pai-ag | 1 |
| 188 | paoz/fio2 | 1 |
| 189 | patients/surrogates | 1 |
| 190 | plentifully | 1 |
| 191 | pneumonia-were | 1 |
| 192 | possible.we | 1 |
| 193 | problem-centered | 1 |
| 194 | purpose-we | 1 |
| 195 | r-s6 | 1 |
| 196 | rasfs | 1 |
| 197 | rebeldía | 1 |
| 198 | received.we | 1 |
| 199 | remorseful | 1 |
| 200 | rhfgf | 1 |
| 201 | rhh+rch | 1 |
| 202 | risk-factor-adjusted | 1 |
| 203 | rmhs-treated | 1 |
| 204 | rplc/sfc | 1 |
| 205 | rs1410996 | 1 |
| 206 | ruberg | 1 |
| 207 | s-1-cisplatin | 1 |
| 208 | sandblasted+liner | 1 |
| 209 | schulz-dubois | 1 |
| 210 | scvo2≥0.70 | 1 |
| 211 | self-mobilizations | 1 |
| 212 | serum-ctx-i | 1 |
| 213 | signs.we | 1 |
| 214 | simultaneoulsy | 1 |
| 215 | sino-western | 1 |
| 216 | slc39a14 | 1 |
| 217 | small-range | 1 |
| 218 | su3 | 1 |
| 219 | sulfanilamide/4-aminoethylbenzenesulfonamide | 1 |
| 220 | swan-ganz-catheterization | 1 |
| 221 | tactually | 1 |
| 222 | telegraphically | 1 |
| 223 | terminolaterally | 1 |
| 224 | triallelically | 1 |
| 225 | trypsin-chymotrypsin-pepsin | 1 |
| 226 | unsignificantly | 1 |
| 227 | venues/activities | 1 |
| 228 | vilaseca | 1 |
| 229 | wetsuits | 1 |
| 230 | wheeziness | 1 |
| 231 | x-rays/scans | 1 |
| 232 | xeno-tumor | 1 |
| 233 | yozgat | 1 |
| 234 | zvi/air | 1 |
| 235 | £27,360 | 1 |
| 236 | αc18:3 | 1 |
| 237 | €31,211 | 1 |
| 238 | △h | 1 |
| 239 | ⩾1.5-fold | 1 |
| 1 | 'assess | 1 |
| 2 | +3187a-g. | 1 |
| 3 | 0.47±0.26 | 1 |
| 4 | 02/2010 | 1 |
| 5 | 06.07.1999 | 1 |
| 6 | 1-cyano-4,5-epithiopentane | 1 |
| 7 | 1.4±1.4 | 1 |
| 8 | 1.94±2.31 | 1 |
| 9 | 10-μl | 1 |
| 10 | 11-hete | 1 |
| 11 | 11.7±2.7 | 1 |
| 12 | 13,049 | 1 |
| 13 | 13,658 | 1 |
| 14 | 16,454 | 1 |
| 15 | 16mls | 1 |
| 16 | 2.57/1,000 | 1 |
| 17 | 2.60-folds | 1 |
| 18 | 20,020 | 1 |
| 19 | 20,654 | 1 |
| 20 | 20/40°c | 1 |
| 21 | 20/twice | 1 |
| 22 | 2011were | 2 |
| 23 | 3.3-times | 1 |
| 24 | 3894 | 1 |
| 25 | 4-methoxyquinolone-decayed | 1 |
| 26 | 405/487 | 1 |
| 27 | 41,831 | 1 |
| 28 | 42,742 | 2 |
| 29 | 5,344 | 2 |
| 30 | 5,494 | 1 |
| 31 | 5,6,11-trideoxyttx | 2 |
| 32 | 5,762 | 1 |
| 33 | 5,997 | 1 |
| 34 | 5-insp7 | 3 |
| 35 | 5α/5β-thf | 1 |
| 36 | 6-acid | 1 |
| 37 | 6g/l | 1 |
| 38 | 82/92 | 1 |
| 39 | 83,973 | 1 |
| 40 | 8361 | 1 |
| 41 | 84,646 | 1 |
| 42 | 8638 | 1 |
| 43 | 9,318 | 1 |
| 44 | acedapsone | 1 |
| 45 | actts | 1 |
| 46 | adoptively | 13 |
| 47 | agurya | 1 |
| 48 | akhawaynī | 2 |
| 49 | alpha-2b/ribavirin | 1 |
| 50 | alpha7beta1 | 1 |
| 51 | anamnestically | 1 |
| 52 | androstane-3α,17β-diol-17-glucuronide | 1 |
| 53 | anitschkow | 1 |
| 54 | anti-c-src | 1 |
| 55 | apolipoprotein-b/ciii | 1 |
| 56 | apxs | 1 |
| 57 | arachnia | 2 |
| 58 | avf/taf | 1 |
| 59 | avicenol-c. | 1 |
| 60 | b-surgery | 1 |
| 61 | benchmrk-2 | 1 |
| 62 | bignami | 2 |
| 63 | biobody-78 | 2 |
| 64 | bmp-iir | 1 |
| 65 | boc-deprotection | 1 |
| 66 | brittain | 3 |
| 67 | butylidenephthalide | 2 |
| 68 | buzzes | 1 |
| 69 | c-ha-ras | 1 |
| 70 | c-maltodextrin-glucose | 1 |
| 71 | c-mets | 1 |
| 72 | cd11a-mrna | 1 |
| 73 | cephtriaxon | 1 |
| 74 | cfr=stress | 1 |
| 75 | chd2 | 6 |
| 76 | cholesterol-4-14c | 1 |
| 77 | cl-alb | 1 |
| 78 | co-renitec | 1 |
| 79 | conducted.when | 1 |
| 80 | conjugatively | 1 |
| 81 | conrardy | 1 |
| 82 | coprologically | 1 |
| 83 | cr-calu1 | 2 |
| 84 | csf-oligosaccharides | 1 |
| 85 | cys-gly | 2 |
| 86 | cystolithopaxy | 1 |
| 87 | d-mannono-1,4-lactone | 1 |
| 88 | d2-4 | 1 |
| 89 | das-remission | 1 |
| 90 | demets.2 | 1 |
| 91 | desensitization-was | 1 |
| 92 | dft-pbe | 1 |
| 93 | diacetylation | 1 |
| 94 | dobmax | 4 |
| 95 | dogwood | 2 |
| 96 | early-responders | 2 |
| 97 | ecfp-hspb6 | 2 |
| 98 | echinocytosis | 1 |
| 99 | edsuvmean | 2 |
| 100 | electroclinically | 1 |
| 101 | engenderhealth | 1 |
| 102 | epicutaneously | 1 |
| 103 | evocarpine | 2 |
| 104 | ezetimibe+phytosterols | 1 |
| 105 | fads2-activities | 1 |
| 106 | fes-therapy | 1 |
| 107 | financially-equipped | 1 |
| 108 | fluticasone.ciclesonide | 1 |
| 109 | fodders | 3 |
| 110 | folk-healers | 1 |
| 111 | gan-stagnancy | 4 |
| 112 | gate-control-theory | 1 |
| 113 | giao-hf/6-31g*//b3lyp/6-31g* | 1 |
| 114 | gln13 | 1 |
| 115 | h-alpha | 1 |
| 116 | h460-were | 1 |
| 117 | habert | 1 |
| 118 | headache.we | 1 |
| 119 | hf.we | 1 |
| 120 | hilleke | 5 |
| 121 | his176 | 1 |
| 122 | hspb2b3 | 4 |
| 123 | human-colon-15/mdr | 1 |
| 124 | hydroxychlorochine | 1 |
| 125 | hyposalinity | 1 |
| 126 | i1+3 | 1 |
| 127 | ibis2 | 1 |
| 128 | id9 | 1 |
| 129 | il-12/il-10 | 2 |
| 130 | iliacs | 1 |
| 131 | included.oral | 1 |
| 132 | inf-10 | 1 |
| 133 | irm2 | 2 |
| 134 | jdp2 | 1 |
| 135 | kammerman | 1 |
| 136 | kindly | 3 |
| 137 | kruckman | 1 |
| 138 | l-gly | 2 |
| 139 | lambo | 1 |
| 140 | lanphear | 4 |
| 141 | lc/pda/ms | 1 |
| 142 | lennon | 1 |
| 143 | lidocaine-desipramine | 1 |
| 144 | long-running | 1 |
| 145 | lower.. | 1 |
| 146 | lvring→rv-were | 1 |
| 147 | m-2were | 1 |
| 148 | mandarin-speakers | 2 |
| 149 | masssensation | 1 |
| 150 | me/ge | 1 |
| 151 | meaningful-has | 1 |
| 152 | mip1-β | 1 |
| 153 | mlvss | 1 |
| 154 | mn4 | 1 |
| 155 | mock-vector | 1 |
| 156 | mtor2 | 1 |
| 157 | muses | 1 |
| 158 | n-deacylation | 1 |
| 159 | naringenin-receptor | 1 |
| 160 | nmeps | 1 |
| 161 | no-cells | 2 |
| 162 | non-platform | 1 |
| 163 | nonradiologists | 1 |
| 164 | oil-yielding | 1 |
| 165 | ornish-were | 1 |
| 166 | oxaceprolin | 1 |
| 167 | pai-ag | 1 |
| 168 | paoz/fio2 | 1 |
| 169 | pathomorphologically | 2 |
| 170 | patients/surrogates | 1 |
| 171 | plentifully | 1 |
| 172 | pneumonia-were | 1 |
| 173 | polythiazide | 2 |
| 174 | possible.we | 1 |
| 175 | postflap | 2 |
| 176 | pre-mir-125b | 3 |
| 177 | problem-centered | 1 |
| 178 | psca-hsp | 2 |
| 179 | purpose-we | 1 |
| 180 | r-s6 | 1 |
| 181 | rasfs | 1 |
| 182 | rebeldía | 1 |
| 183 | received.we | 1 |
| 184 | remorseful | 1 |
| 185 | results- | 7 |
| 186 | rhfgf | 1 |
| 187 | rhh+rch | 1 |
| 188 | risk-factor-adjusted | 1 |
| 189 | rmhs-treated | 1 |
| 190 | rplc/sfc | 1 |
| 191 | rs1410996 | 1 |
| 192 | ruberg | 1 |
| 193 | s-1-cisplatin | 1 |
| 194 | s7c15 | 4 |
| 195 | sandblasted+liner | 1 |
| 196 | schulz-dubois | 1 |
| 197 | scvo2≥0.70 | 1 |
| 198 | self-mobilizations | 1 |
| 199 | serum-ctx-i | 1 |
| 200 | shedded | 3 |
| 201 | signs.we | 1 |
| 202 | simultaneoulsy | 1 |
| 203 | sino-western | 1 |
| 204 | slc39a14 | 1 |
| 205 | small-range | 1 |
| 206 | strupp | 6 |
| 207 | su3 | 1 |
| 208 | sulfanilamide/4-aminoethylbenzenesulfonamide | 1 |
| 209 | supracrestally | 3 |
| 210 | swan-ganz-catheterization | 1 |
| 211 | tactually | 1 |
| 212 | tbody-tscrotum | 2 |
| 213 | telegraphically | 1 |
| 214 | terminolaterally | 1 |
| 215 | then | 18,090 |
| 216 | thence | 7 |
| 217 | three.we | 3 |
| 218 | tranquileyes™ | 2 |
| 219 | trans-mdmar | 3 |
| 220 | triallelically | 1 |
| 221 | tribally | 2 |
| 222 | trypsin-chymotrypsin-pepsin | 1 |
| 223 | tymofyeyev | 2 |
| 224 | unsignificantly | 1 |
| 225 | venues/activities | 1 |
| 226 | vilaseca | 1 |
| 227 | wetsuits | 1 |
| 228 | wheeziness | 1 |
| 229 | x-rays/scans | 1 |
| 230 | xeno-tumor | 1 |
| 231 | yozgat | 1 |
| 232 | zvi/air | 1 |
| 233 | £27,360 | 1 |
| 234 | αc18:3 | 1 |
| 235 | β-erythroidine | 4 |
| 236 | δgel1δgel7δcwh41 | 2 |
| 237 | €31,211 | 1 |
| 238 | △h | 1 |
| 239 | ⩾1.5-fold | 1 |
| 1 | giao-hf/6-31g*//b3lyp/6-31g* | 1 |
| 2 | results- | 7 |
| 3 | lower.. | 1 |
| 4 | avicenol-c. | 1 |
| 5 | +3187a-g. | 1 |
| 6 | 2.57/1,000 | 1 |
| 7 | inf-10 | 1 |
| 8 | il-12/il-10 | 2 |
| 9 | 02/2010 | 1 |
| 10 | 20,020 | 1 |
| 11 | £27,360 | 1 |
| 12 | scvo2≥0.70 | 1 |
| 13 | €31,211 | 1 |
| 14 | 1.94±2.31 | 1 |
| 15 | 41,831 | 1 |
| 16 | δgel1δgel7δcwh41 | 2 |
| 17 | 8361 | 1 |
| 18 | alpha7beta1 | 1 |
| 19 | cr-calu1 | 2 |
| 20 | benchmrk-2 | 1 |
| 21 | demets.2 | 1 |
| 22 | 42,742 | 2 |
| 23 | 5,762 | 1 |
| 24 | 82/92 | 1 |
| 25 | chd2 | 6 |
| 26 | irm2 | 2 |
| 27 | paoz/fio2 | 1 |
| 28 | jdp2 | 1 |
| 29 | mtor2 | 1 |
| 30 | ibis2 | 1 |
| 31 | i1+3 | 1 |
| 32 | gln13 | 1 |
| 33 | 83,973 | 1 |
| 34 | αc18:3 | 1 |
| 35 | hspb2b3 | 4 |
| 36 | su3 | 1 |
| 37 | d2-4 | 1 |
| 38 | 1.4±1.4 | 1 |
| 39 | slc39a14 | 1 |
| 40 | 5,344 | 2 |
| 41 | 16,454 | 1 |
| 42 | 20,654 | 1 |
| 43 | 5,494 | 1 |
| 44 | 3894 | 1 |
| 45 | mn4 | 1 |
| 46 | s7c15 | 4 |
| 47 | 0.47±0.26 | 1 |
| 48 | 84,646 | 1 |
| 49 | his176 | 1 |
| 50 | rs1410996 | 1 |
| 51 | ecfp-hspb6 | 2 |
| 52 | r-s6 | 1 |
| 53 | 11.7±2.7 | 1 |
| 54 | 405/487 | 1 |
| 55 | 5,997 | 1 |
| 56 | 5-insp7 | 3 |
| 57 | 9,318 | 1 |
| 58 | 8638 | 1 |
| 59 | 13,658 | 1 |
| 60 | biobody-78 | 2 |
| 61 | 13,049 | 1 |
| 62 | 06.07.1999 | 1 |
| 63 | id9 | 1 |
| 64 | vilaseca | 1 |
| 65 | h-alpha | 1 |
| 66 | arachnia | 2 |
| 67 | cd11a-mrna | 1 |
| 68 | agurya | 1 |
| 69 | rebeldía | 1 |
| 70 | pre-mir-125b | 3 |
| 71 | cl-alb | 1 |
| 72 | cholesterol-4-14c | 1 |
| 73 | co-renitec | 1 |
| 74 | rplc/sfc | 1 |
| 75 | anti-c-src | 1 |
| 76 | 20/40°c | 1 |
| 77 | shedded | 3 |
| 78 | financially-equipped | 1 |
| 79 | problem-centered | 1 |
| 80 | rmhs-treated | 1 |
| 81 | risk-factor-adjusted | 1 |
| 82 | 4-methoxyquinolone-decayed | 1 |
| 83 | 6-acid | 1 |
| 84 | ⩾1.5-fold | 1 |
| 85 | dogwood | 2 |
| 86 | dft-pbe | 1 |
| 87 | 20/twice | 1 |
| 88 | thence | 7 |
| 89 | butylidenephthalide | 2 |
| 90 | sulfanilamide/4-aminoethylbenzenesulfonamide | 1 |
| 91 | androstane-3α,17β-diol-17-glucuronide | 1 |
| 92 | fluticasone.ciclesonide | 1 |
| 93 | polythiazide | 2 |
| 94 | me/ge | 1 |
| 95 | small-range | 1 |
| 96 | hilleke | 5 |
| 97 | 1-cyano-4,5-epithiopentane | 1 |
| 98 | β-erythroidine | 4 |
| 99 | hydroxychlorochine | 1 |
| 100 | lidocaine-desipramine | 1 |
| 101 | evocarpine | 2 |
| 102 | acedapsone | 1 |
| 103 | d-mannono-1,4-lactone | 1 |
| 104 | h460-were | 1 |
| 105 | pneumonia-were | 1 |
| 106 | ornish-were | 1 |
| 107 | lvring→rv-were | 1 |
| 108 | 2011were | 2 |
| 109 | m-2were | 1 |
| 110 | c-maltodextrin-glucose | 1 |
| 111 | 11-hete | 1 |
| 112 | purpose-we | 1 |
| 113 | received.we | 1 |
| 114 | three.we | 3 |
| 115 | headache.we | 1 |
| 116 | possible.we | 1 |
| 117 | hf.we | 1 |
| 118 | signs.we | 1 |
| 119 | avf/taf | 1 |
| 120 | rhfgf | 1 |
| 121 | 5α/5β-thf | 1 |
| 122 | pai-ag | 1 |
| 123 | oil-yielding | 1 |
| 124 | long-running | 1 |
| 125 | ruberg | 1 |
| 126 | rhh+rch | 1 |
| 127 | engenderhealth | 1 |
| 128 | △h | 1 |
| 129 | serum-ctx-i | 1 |
| 130 | apolipoprotein-b/ciii | 1 |
| 131 | bignami | 2 |
| 132 | 6g/l | 1 |
| 133 | included.oral | 1 |
| 134 | remorseful | 1 |
| 135 | 10-μl | 1 |
| 136 | non-platform | 1 |
| 137 | tbody-tscrotum | 2 |
| 138 | edsuvmean | 2 |
| 139 | kruckman | 1 |
| 140 | kammerman | 1 |
| 141 | then | 18,090 |
| 142 | conducted.when | 1 |
| 143 | brittain | 3 |
| 144 | oxaceprolin | 1 |
| 145 | alpha-2b/ribavirin | 1 |
| 146 | trypsin-chymotrypsin-pepsin | 1 |
| 147 | s-1-cisplatin | 1 |
| 148 | das-remission | 1 |
| 149 | n-deacylation | 1 |
| 150 | diacetylation | 1 |
| 151 | masssensation | 1 |
| 152 | swan-ganz-catheterization | 1 |
| 153 | boc-deprotection | 1 |
| 154 | lennon | 1 |
| 155 | cephtriaxon | 1 |
| 156 | sino-western | 1 |
| 157 | lambo | 1 |
| 158 | postflap | 2 |
| 159 | strupp | 6 |
| 160 | psca-hsp | 2 |
| 161 | lanphear | 4 |
| 162 | trans-mdmar | 3 |
| 163 | human-colon-15/mdr | 1 |
| 164 | sandblasted+liner | 1 |
| 165 | zvi/air | 1 |
| 166 | bmp-iir | 1 |
| 167 | xeno-tumor | 1 |
| 168 | mock-vector | 1 |
| 169 | naringenin-receptor | 1 |
| 170 | meaningful-has | 1 |
| 171 | c-ha-ras | 1 |
| 172 | desensitization-was | 1 |
| 173 | iliacs | 1 |
| 174 | 2.60-folds | 1 |
| 175 | csf-oligosaccharides | 1 |
| 176 | fads2-activities | 1 |
| 177 | venues/activities | 1 |
| 178 | 3.3-times | 1 |
| 179 | muses | 1 |
| 180 | patients/surrogates | 1 |
| 181 | buzzes | 1 |
| 182 | rasfs | 1 |
| 183 | schulz-dubois | 1 |
| 184 | echinocytosis | 1 |
| 185 | no-cells | 2 |
| 186 | 16mls | 1 |
| 187 | ezetimibe+phytosterols | 1 |
| 188 | lc/pda/ms | 1 |
| 189 | x-rays/scans | 1 |
| 190 | self-mobilizations | 1 |
| 191 | nmeps | 1 |
| 192 | fodders | 3 |
| 193 | early-responders | 2 |
| 194 | mandarin-speakers | 2 |
| 195 | folk-healers | 1 |
| 196 | wheeziness | 1 |
| 197 | cfr=stress | 1 |
| 198 | 'assess | 1 |
| 199 | mlvss | 1 |
| 200 | c-mets | 1 |
| 201 | wetsuits | 1 |
| 202 | nonradiologists | 1 |
| 203 | actts | 1 |
| 204 | apxs | 1 |
| 205 | yozgat | 1 |
| 206 | habert | 1 |
| 207 | tymofyeyev | 2 |
| 208 | anitschkow | 1 |
| 209 | dobmax | 4 |
| 210 | 5,6,11-trideoxyttx | 2 |
| 211 | gan-stagnancy | 4 |
| 212 | conrardy | 1 |
| 213 | kindly | 3 |
| 214 | conjugatively | 1 |
| 215 | adoptively | 13 |
| 216 | l-gly | 2 |
| 217 | cys-gly | 2 |
| 218 | tribally | 2 |
| 219 | pathomorphologically | 2 |
| 220 | coprologically | 1 |
| 221 | telegraphically | 1 |
| 222 | triallelically | 1 |
| 223 | electroclinically | 1 |
| 224 | anamnestically | 1 |
| 225 | terminolaterally | 1 |
| 226 | supracrestally | 3 |
| 227 | tactually | 1 |
| 228 | plentifully | 1 |
| 229 | epicutaneously | 1 |
| 230 | unsignificantly | 1 |
| 231 | fes-therapy | 1 |
| 232 | b-surgery | 1 |
| 233 | gate-control-theory | 1 |
| 234 | simultaneoulsy | 1 |
| 235 | hyposalinity | 1 |
| 236 | cystolithopaxy | 1 |
| 237 | tranquileyes™ | 2 |
| 238 | akhawaynī | 2 |
| 239 | mip1-β | 1 |